Industries > Pharma > Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

PUBLISHED: 27 February 2018
PAGES: 204
PRODUCT CODE: PHA0288

Clear
WOOCS 2.2.1

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 74 figures– all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biosimilar Monoclonal Antibodies Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

• This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
• Remsima/Inflectra
• Infimab
• Reditux
• BI695500
• CT-P10
• BI695501
• FKB327
• FKB238
• Mabtas
• AcellBia
• Maball
• Clotinab
• Abcixirel
• BCD-022
• BCD-021
• Herzuma
• CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
• The US Biosimilar mAb Market
• Japanese Biosimilar mAb Market
• EU5 Biosimilar mAb Markets
• BRIC and South Korea Biosimilar mAb Markets
• Rest of the World Biosimilar mAb Market

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories